SARS-CoV-2亚单位疫苗研究现状与挑战  

Advances and challenges in research on SARS-CoV-2 subunit vaccine candidates

作　　者：杨柏峰 张家友 李启明 YANG Bai-feng;ZHANG Jia-you;LI Qi-ming(Wuhan Institute of Biological Products Co.,Ltd.,Wuhan 430207,Hubei Province,China)

机构地区：[1]武汉生物制品研究所有限责任公司,湖北武汉430207 [2]国家联合疫苗工程技术研究中心,湖北武汉430207 [3]国药中生生物技术研究院有限公司,北京101111

出　　处：《中国生物制品学杂志》2021年第8期889-897,共9页Chinese Journal of Biologicals

摘　　要：由重症急性呼吸综合征冠状病毒2型(severe acute respiratory syndrome coronavirus 2,SARS-Co V-2)引起的2019冠状病毒病(Coronavirus Disease 2019,COVID-19)大流行给全球社区、医疗系统和经济带来前所未有的压力。疫苗的成功研发及使用给有效应对COVID-19带来了希望。亚单位疫苗最有希望作为"primer-boost"策略中加强免疫的候选疫苗之一,已成为主要的新冠候选疫苗。本文对目前进入临床试验的亚单位疫苗、构建平台技术及最新进展作一综述,并对亚单位疫苗开发中所遇到的挑战进行探讨。The Coronavirus Disease 2019(COVID-19)pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has brought unprecedented pressure on communities,medical systems and economy all over the world.Candidate vaccines have been generated using existing technologies that provides us with the hope to effectively deal with COVID-19.Subunit vaccines are one of the prominent options in the“primer-boost”strategy,and have become the main force in the new candidate vaccines.This paper reviews the latest progress in clinical trials and platforms technology and highlight the challenges encountered in the development of COVID-19 subunit vaccine.

关 键 词：重症急性呼吸综合征冠状病毒2型 亚单位疫苗 表达系统 佐剂 临床终点评价 

分 类 号：R186[医药卫生—流行病学]